Abrupt discontinuation after prolonged use is not recommended
Inhalation doses should be reduced to the lowest effective dose once asthma stability has been achieved.
Concomitant use with strong CYP450 3A4 inhibitors is not recommended.
Oral Corticosteroids :
-Allow at least 1 week before initiating a taper with oral corticosteroid
-Prednisone should be reduced in increments not exceeding mg to 5 mg per day on a weekly basis
-Monitor for signs of asthma instability including serial objective measure of airflow
-Monitor for signs of adrenal insufficiency
Whilst the use of inhaled steroids and long acting beta-adrenoceptor agonists (LABA) are recommended in asthma guidelines for the resulting improved symptom control,  concerns have been raised that salmeterol may increase the small risks of asthma deaths and this additional risk is not reduced with the additional use of inhaled steroids.  Other side effects from this drug combination may include increased blood pressure, change in heart rate, an irregular heartbeat, increased risk of osteoporosis, cataracts, and glaucoma.